Bellicum Pharmaceuticals Inc (BLCM)

2.07 -0.16  -7.17% NASDAQ Oct 22, 16:00 2.07 0.00  0.00% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All BLCM News

News

View All Events

Events

Date Type Description
11/05/2021 Earnings Results Q3 2021 Earnings Results
11/05/2021 Earnings Calls Q3 2021 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.
  • URL: http://www.bellicum.com
  • Investor Relations URL: http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-irhome
  • HQ State/Province: Texas
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Nov. 05, 2021
  • Last Earnings Release: Nov. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.